Acquisition marks expanded sector growth


Strengthening its fi eld of expertise in the gas generation market Dusty TLP, owner of Peak Scientifi c, has announced the acquisition of Wirac Automation Ltd, which is trading as Noblegen. This latest expansion of its portfolio and product development to better serve customers around the world represents a signifi cant milestone for the holding company, as it extends the ownership group’s presence into new sectors while enhancing its current specialist industry position.


In recognition of the talent and expertise at Noblegen, the new owners have committed to fostering a collaborative environment where employees can continue to thrive and contribute to the company’s success.


Noblegen will remain a separate brand from Peak Scientifi c, maintaining its own identity and continuing to operate independently, now with the support of a world leading laboratory gas generation company.


Paul Hudson, newly appointed General Manager for Noblegen commented: “I am thrilled to take up this exciting opportunity with the team at Noblegen to continue bringing their existing customers the excellent products and customer service they have come to expect from Noblegen.”


Bill Johnston, founder of Wirac Automation Ltd, who will continue working at Noblegen in the role of Technical Director, commented on the change of ownership, “I’d like to thank all of our customers and suppliers who have been part of the business’s success over the years and I fi rmly believe that under the new ownership even greater successes are to be had in the years ahead.”


Peak Scientifi c’s owners are confi dent that the acquisition of Noblegen will also create new opportunities for collaboration and innovation, with both companies continue to drive positive change in the industries they serve.


Production Floor at PEAK Scientifi c


More information online: ilmt.co/PL/EVnj 62211pr@reply-direct.com


Fundraiser benefits support group for children with tumours


Appointment supports accelerated growth in US OOC market


Organ-on-a-chip (OOC) company CN Bio has appointed Joe Parisi as US Director of Sales, where he will lead expansion of activities for customers looking to harness the company’s range of microphysiological systems (MPS) to meet demand for new alternative methodologies (NAMs) in preclinical drug discovery. With global demand for microphysiological systems (MPS) having accelerated, particularly in the US, his will provide a local source of expertise supporting customers to improve the human relevance of preclinical workfl ows and reduce animal model reliance.


Offi cial presentation of the donation at the Zeiss site in Oberkochen (l. to r.): Gerhard Bösner (Zeiss SMT Worker’s Council), Artur Franzke (Zeiss SMT Worker’s Council), Elvira Wäckerle (Ulm Support Group), Dr. Jens Werner (Zeiss SMT Management) and Richard Wäckerle (Ulm Support Group) (Credit: Zeiss)


A fundraising campaign organised by the Worker’s Council of the Semiconductor Manufacturing Technology (SMT) segment of Zeiss (Oberkochen) has raised €42,000 for the Ulm Support Group for Children with Tumours and Leukaemia (“Förderkreis Ulm für tumor- und leukämiekranke Kinder e.V.”).


This traditional annual fundraiser supporting projects in the region is held every year during the Christmas season. The campaign raised money from the sale of around 2,600 lottery tickets at the company’s site, with further on-line donations made by more than 150 employees The SMT Management team then doubled what was already a record sum raised of just under €21,000 to make a grand total of €42,000. In past years money was raised for regional initiatives and organisations such as the Kinderstiftung Knalltüte or the food banks in Aalen and Heidenheim.


The various forms of leukemia are malignant diseases of the hematopoietic (blood-forming) system and, at about 30% of all malignant neoplasms, constitute the most frequent cancers in children and young people. “A diagnosis of this nature is a severe blow for the families and the life of everyone affected is turned upside down,” emphasised Artur Frantzke, Deputy Chairman of the Zeiss SMT Worker’s Council in Oberkochen. “The large sum raised demonstrates our commitment to this important cause.”


Dr. Jens Werner, HR Manager of Zeiss SMT and a member of the Management team added, “It always makes us proud that in spite of our privileged position, we as a company never lose sight of those who are less fortunate than ourselves. Therefore a big thank-you is due to all colleagues for their commitment.”


The support group, which relies 100% on fi nancing, already has preliminary plans for the fund, including subsidy of a support clinic at the Ulm University Hospital, as well as activities such as goody boxes, days out or music therapy.


More information online: ilmt.co/PL/A6yx 62280pr@reply-direct.com


Karen Curran


CRO Veramed has announced the appointment of Karen Curran as Chief Strategy Offi cer at a time of substantial global growth for the organisation, which operates as a partner for the whole biometrics value chain, including statistical consultancy, data management, FSP services, clinical trial reporting and automation, DMC and evidence and value generation.


With over 25 years’ experience in the industry, Karen’s role with the specialist biometrics CRO will be to work closely with pharmaceutical and biotech companies to establish innovative data


With a strong track record in delivering successful sales strategies across the biotechnology sector, Joe was formerly Director of Sales for US West (acquired by Bruker Corporation in 2023), with responsibility for growing the proteomics side of the business. At Purigen Biosystems (acquired by Bionano Genomics in 2022), he was Director of West Coast Sales, overseeing commercial development and supporting the Company’s growth from start-up to commercial success over three years. He has also held senior roles at numerous life sciences organisations, including Isoplexis, NanoString Technologies, and Life Technologies. Joe has a BSc in Molecular and Cellular Biology from the University of Illinois Urbana-Champaign.


“The potential offered by CN Bio’s PhysioMimix range, substantiated by the Company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve effi ciency and minimize drug failures. In my new role, I look forward to harnessing my experience within the sector to support the design and implementation of a commercial strategy that will enable us to meet the signifi cant demand for animal model alternatives here in the US,” he said


Joe Parisi


CN Bio’s chief executive offi cer Dr Paul Brooks, said: “It is great to welcome Joe to the team. Throughout his career, he has repeatedly demonstrated his expertise in biotech sales, with a proven history of success across companies at all stages of growth and commercialisation. Joe’s appointment represents an important milestone in CN Bio’s growth, having successfully built a strong international presence and now looking to expand this further into the US, a key market for innovative drug discovery.”


More information online: ilmt.co/PL/92Q1 62089pr@reply-direct.com


CSO joins during period of growth management, statistics and statistical programming partnerships.


Recognised as an industry leader with ability to develop and expand pharmaceutical services businesses globally, her deep market knowledge enables her to provide strategic guidance and devise inventive solutions for biometric processes, including CDISC adoption and implementation, across large and small pharma and CRO environments. She has a track record of supporting successful submissions to regulatory bodies such as the FDA, EMEA and the PMDA. Karen actively contributes to the Global Healthcare Data Science Community Hub PHUSE and currently serves on the CDISC Board of Directors.


“I’m thrilled to have joined Veramed at such an exciting stage of growth,” said Karen. “I look forward to collaborating with our clients and partners to pioneer innovative solutions that meet both short and long-term goals, leading to more effi cient and meaningful partnership models.”


Matt Jones, Co-Founder and CEO of Veramed, expressed his enthusiasm about Karen joining the team: “We’re excited to have Karen on board as Chief Strategy Offi cer as we solidify our position as the industry’s CRO of choice.”


More information online: ilmt.co/PL/DZy5 62288pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68